Canopy Growth Corporation
CGCHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Canopy Growth Corporation focuses on Drug Manufacturers - Specialty & Generic services and products. Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany,. The $303.6M market capitalization puts CGC squarely in small-cap range for its industry. The company operates through two segments, Cannabis and Storz & Bickel.
Market Cap
$303.6M
Beta
2.37
P/E (TTM)
—
P/E (Fwd)
-5.58
EPS (TTM)
$-0.45
EPS (Fwd)
$-0.12
ROE
-39.5%
ROA
-3.9%
Cash
$337.8M
Total Debt
$277.3M
Free CF
$7.2M
52W Change
-48.8%
Annual Financials
Cash vs Debt
Where CGC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CGC finished 27.27% below its 150-day moving average ($0.99) and 29.41% below its 200-day moving average ($1.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CGC overbought or oversold?
At the October 20, 2026 close, CGC's RSI(14) was 15.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Canopy Growth Corporation holds $337.8M in cash against $277.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $7.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -39.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $333.3M (2023) to $284.6M (2026), a 15% decline worth watching.
Canopy Growth Corporation's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Canopy Growth Corporation's trajectory.